Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345244 | 1.00 | KMT2A (0.56) | KMT2AGAATP53MAPTL3MBTL1 | |
| SCHEMBL1345434 | 1.00 | KMT2A (0.56) | KMT2AGAATP53MAPTL3MBTL1 | |
| SCHEMBL3529478 | 0.84 | SLC6A3 (0.56) | KMT2AGAAMAPTSLC6A3MEN1 | |
| SCHEMBL2874789 | 0.84 | SLC6A3 (0.52) | KMT2AGAAMAPTSLC6A3HTT | |
| SCHEMBL4136472 | 0.83 | ALDH1A1 (0.58) | KMT2AGAAMAPTL3MBTL1RAB9A | |
| SCHEMBL9309607 | 0.83 | SLC6A3 (0.49) | KMT2AGAATP53MAPTSLC6A3 | |
| SCHEMBL22838115 | 0.83 | SLC6A3 (0.49) | KMT2AGAATP53MAPTSLC6A3 | |
| SCHEMBL8593569 | 0.83 | MEN1 (0.59) | KMT2AGAAMAPTSLC6A3MEN1 | |
| SCHEMBL2614715 | 0.83 | MEN1 (0.59) | KMT2AGAAMAPTSLC6A3MEN1 | |
| SCHEMBL550633 | 0.82 | KMT2A (0.52) | KMT2AGAATP53MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743082-A1 | CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION | UCL Business Ltd (GB) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025012634-A1 | CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | WO | disclosed |
| US-20220062428-A1 | Prodrugs with a tridentate self-immolative linker | THE GENERAL HOSPITAL CORPORATION | 2022-03-03 | — | — | US | disclosed |
| US-20170191986-A1 | Compounds and Method of Identifying, Synthesizing, Optimizing and Profiling Protein Modulators | HMI Medical Innovations, LLC | 2017-07-06 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8604029-B2 | 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents | F2G LTD BRITISH BODY CORPORATE (GB) | 2013-12-10 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8247556-B2 | Method for preparing 6-substituted-7-aza-indoles | AMGEN INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| CN-1319957-C | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007048070-A2 | PYRROLO-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | AMGEN INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| CN-1549809-A | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | ������������ʽ���� | 2004-11-24 | — | — | CN | disclosed |
| EP-1422224-A1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | Shiseido Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-4650810-A | OR INDOLE-5-THIOACETAMIDES | GLAXO GROUP LIMITED (GB) | 1987-03-17 | — | — | US | disclosed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
| US-4476315-A | NITROARYLACETIC ACID ESTERS FROM NITROAROMATIC COMPOUNDS | ETHYL CORPORATION (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0077662-A1 | Preparation of nitroarylacetic acid esters and derivatives thereof | ETHYL CORPORATION (US) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062428-A1 | Prodrugs with a tridentate self-immolative linker | DNTT, SLC29A1, TK1 | KMT2A 2908/4885GAA 472/4885TP53 719/4885 |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | MMP1, MMP2, MMP3 | KMT2A 2099/4885GAA 785/4885TP53 2745/4885 |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | KMT2A 1046/4885GAA 999/4885TP53 663/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | KMT2A 3897/4885GAA 57/4885TP53 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.